A paper to be presented at the Genitourinary Cancers Synposium today, suggests that use of a liquid biopsy and analysis of single circulating tumor cells (CTCs) may be helpful in determining therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). The paper by Scher et al. (abstract no. 163; “Single CTC characterization to identify phenotypic […]![]()
